To resolve some of the obstacles linked to using patient-derived organoids (PDOs) in large-scale screens, like assay reproducibility and scalability, a semi-automated bioprocess was constructed for the controlled production of at-scale standardized PDOs.
Image Credit: Molecular Devices
Molecular Devices developed an end-to-end, automated workflow, beginning with assay-ready colorectal cancer organoids, comprising establishment in culture, maintenance, and screening. Automation protocols were applied for routine monitoring in culture, pre- and post-treatment. Compound effects were also monitored over time.
Organoid growth and development were assessed via a deep learning-based image segmentation model, which automated the segmentation of the organoids. The organoids utilized had been expanded previously via Molecular Devices’* bioprocess and then frozen, allowing access to a significant amount of standardized, assay-ready organoids, enabling a more statistically robust screen.
Through this method, Molecular Devices monitored the impact of different compounds on colorectal organoid size, morphology, texture, and other morphological and phenotypic parameters.
Their findings demonstrate the higher potential of PDOs than other tissues in precision medicine and high-throughput drug discovery use cases when utilizing automation with high-content imaging.
*Molecular Devices acquired Cellesce in 2022.
Download Now
About Molecular Devices UK Ltd 
Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications.
Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over 1,000 associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion.
To learn more about how Molecular Devices helps fast-track scientific discovery, visit www.moleculardevices.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.